[1]
Jain S, Malinowski M, Chopra P, Varshney V, Deer TR. Intrathecal drug delivery for pain management: recent advances and future developments. Expert opinion on drug delivery. 2019 Aug:16(8):815-822. doi: 10.1080/17425247.2019.1642870. Epub 2019 Jul 19
[PubMed PMID: 31305165]
Level 3 (low-level) evidence
[2]
Olesen J. From ICHD-3 beta to ICHD-3. Cephalalgia : an international journal of headache. 2016 Apr:36(5):401-2. doi: 10.1177/0333102415596446. Epub 2015 Jul 10
[PubMed PMID: 26162775]
[3]
Lanteri-Minet M, Donnet A. Hypnic headache. Current pain and headache reports. 2010 Aug:14(4):309-15. doi: 10.1007/s11916-010-0124-8. Epub
[PubMed PMID: 20512536]
[4]
Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia : an international journal of headache. 2004:24 Suppl 1():9-160
[PubMed PMID: 14979299]
[5]
Liang JF, Wang SJ. Hypnic headache: a review of clinical features, therapeutic options and outcomes. Cephalalgia : an international journal of headache. 2014 Sep:34(10):795-805. doi: 10.1177/0333102414537914. Epub 2014 Jun 18
[PubMed PMID: 24942086]
[6]
Holle D, Naegel S, Obermann M. Hypnic headache. Cephalalgia : an international journal of headache. 2013 Dec:33(16):1349-57. doi: 10.1177/0333102413495967. Epub 2013 Jul 5
[PubMed PMID: 23832130]
[7]
Donnet A, Lantéri-Minet M. A consecutive series of 22 cases of hypnic headache in France. Cephalalgia : an international journal of headache. 2009 Sep:29(9):928-34. doi: 10.1111/j.1468-2982.2008.01826.x. Epub 2009 Feb 24
[PubMed PMID: 19250282]
Level 3 (low-level) evidence
[8]
Holle D, Naegel S, Krebs S, Gaul C, Gizewski E, Diener HC, Katsarava Z, Obermann M. Hypothalamic gray matter volume loss in hypnic headache. Annals of neurology. 2011 Mar:69(3):533-9. doi: 10.1002/ana.22188. Epub 2010 Nov 8
[PubMed PMID: 21446025]
[10]
Evers S, Goadsby PJ. Hypnic headache: clinical features, pathophysiology, and treatment. Neurology. 2003 Mar 25:60(6):905-9
[PubMed PMID: 12654950]
[11]
Goadsby PJ. Unique Migraine Subtypes, Rare Headache Disorders, and Other Disturbances. Continuum (Minneapolis, Minn.). 2015 Aug:21(4 Headache):1032-40. doi: 10.1212/CON.0000000000000195. Epub
[PubMed PMID: 26252589]
[12]
Dodick DW, Mosek AC, Campbell JK. The hypnic ("alarm clock") headache syndrome. Cephalalgia : an international journal of headache. 1998 Apr:18(3):152-6
[PubMed PMID: 9595209]
[13]
Peatfield RC, Mendoza ND. Posterior fossa meningioma presenting as hypnic headache. Headache. 2003 Oct:43(9):1007-8
[PubMed PMID: 14511280]
[14]
Jain S, Silberstein SD. Invited Commentary on Preventive Anti-Migraine Therapy (PAMT). Current treatment options in neurology. 2019 Mar 14:21(4):14. doi: 10.1007/s11940-019-0555-4. Epub 2019 Mar 14
[PubMed PMID: 30868470]
Level 3 (low-level) evidence
[15]
Ivañez V, Soler R, Barreiro P. Hypnic headache syndrome: a case with good response to indomethacin. Cephalalgia : an international journal of headache. 1998 May:18(4):225-6
[PubMed PMID: 9642499]
Level 3 (low-level) evidence
[16]
Seidel S, Zeitlhofer J, Wöber C. First Austrian case of hypnic headache: serial polysomnography and blood pressure monitoring in treatment with indomethacin. Cephalalgia : an international journal of headache. 2008 Oct:28(10):1086-90. doi: 10.1111/j.1468-2982.2008.01611.x. Epub 2008 May 21
[PubMed PMID: 18498399]
Level 3 (low-level) evidence
[18]
Marziniak M, Voss J, Evers S. Hypnic headache successfully treated with botulinum toxin type A. Cephalalgia : an international journal of headache. 2007 Sep:27(9):1082-4
[PubMed PMID: 17645763]
[19]
Son BC, Yang SH, Hong JT, Lee SW. Occipital nerve stimulation for medically refractory hypnic headache. Neuromodulation : journal of the International Neuromodulation Society. 2012 Jul:15(4):381-6. doi: 10.1111/j.1525-1403.2012.00436.x. Epub 2012 Feb 29
[PubMed PMID: 22376140]
[20]
Deer TR, Grider JS, Lamer TJ, Pope JE, Falowski S, Hunter CW, Provenzano DA, Slavin KV, Russo M, Carayannopoulos A, Shah JM, Harned ME, Hagedorn JM, Bolash RB, Arle JE, Kapural L, Amirdelfan K, Jain S, Liem L, Carlson JD, Malinowski MN, Bendel M, Yang A, Aiyer R, Valimahomed A, Antony A, Craig J, Fishman MA, Al-Kaisy AA, Christelis N, Rosenquist RW, Levy RM, Mekhail N. A Systematic Literature Review of Spine Neurostimulation Therapies for the Treatment of Pain. Pain medicine (Malden, Mass.). 2020 Nov 7:21(7):1421-1432. doi: 10.1093/pm/pnz353. Epub
[PubMed PMID: 32034422]
Level 1 (high-level) evidence
[21]
Jain S, Fishman MA, Wu C. Significant cephalad lead migration with use of externally powered spinal cord stimulator. BMJ case reports. 2018 Sep 21:2018():. pii: bcr-2018-225813. doi: 10.1136/bcr-2018-225813. Epub 2018 Sep 21
[PubMed PMID: 30244224]
Level 3 (low-level) evidence
[22]
Deer TR, Jain S, Hunter C, Chakravarthy K. Neurostimulation for Intractable Chronic Pain. Brain sciences. 2019 Jan 24:9(2):. doi: 10.3390/brainsci9020023. Epub 2019 Jan 24
[PubMed PMID: 30682776]
[23]
Jain S, Yuan H, Spare N, Silberstein SD. Erenumab in the treatment of migraine. Pain management. 2018 Nov 1:8(6):415-426. doi: 10.2217/pmt-2018-0037. Epub 2018 Sep 21
[PubMed PMID: 30235976]
[26]
Tariq N, Estemalik E, Vij B, Kriegler JS, Tepper SJ, Stillman MJ. Long-Term Outcomes and Clinical Characteristics of Hypnic Headache Syndrome: 40 Patients Series From a Tertiary Referral Center. Headache. 2016 Apr:56(4):717-24. doi: 10.1111/head.12796. Epub 2016 Mar 26
[PubMed PMID: 27015738]